[Updated 1:33 p.m.] Intra-Cellular Therapies will have to wait another three months to see whether the FDA will approve its experimental drug for schizophrenia, which has produced mixed results in human studies but is currently under a regulatory review.
The New York company said Monday that the FDA has pushed back the deadline for its review of the drug lumateperone until Dec. 27 so the agency can review information from safety studies in animals. Intra-Cellular (NASDAQ: ITCI) is confident it can answer the agency’s questions and plans to respond in the coming weeks, CEO Sharon Mates said on… Read more »
UNDERWRITERS AND PARTNERS
